I find it very positive when the price is up on low volume and random indictments appear against the CEO of a company with a transformative medicine that will upend the pharmaceutical landscape.
Meanwhile the rest of us gladly hold our shares and wait on the impending substantive news.
That’s the opinion from the long and glass half full corner.